Macugen

PreclinicalSmall molecule

Pfizer

Macugen is one of 41 small molecule programs targeting Macular Degeneration. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular DegenerationActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Macular DegenerationPreclinical

Active, not recruiting

Diabetic RetinopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Avapro

Sanofi

Approved

1 3

Farxiga

Tricor

3 5

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

EGRIFTA WR

TTheratechnologies

Approved

1 7

Decadron

AAspen Global Incorporated

Glucophage

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lodosyn

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Macular Degeneration2 trials

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

Withdrawn· Pfizer logo

Pfizer··NCT00820742

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Completed· Pfizer logo

Pfizer··NCT00460408·501 enrolled

Age-Related Macular Degeneration2 trials

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

Completed· Pfizer logo

Pfizer··NCT00549055·38 enrolled

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Completed·EEyetech Pharmaceuticals·Phase 2·NCT00087763·135 enrolled

Safety and Efficacy1 trial

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00605280·317 enrolled

Proliferative Diabetic Retinopathy1 trial

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

Withdrawn·GGreater Houston Retina Research·Phase 3·NCT01589718

Diabetic Retinopathy1 trial

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT00446381·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Macugen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Macugen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Macugen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Macugen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Macular Degeneration2 trials

Age-Related Macular Degeneration2 trials

Safety and Efficacy1 trial

Proliferative Diabetic Retinopathy1 trial

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News